ZA949301B - Heterocyclic benzenesulfonylimine derivatives AS inhibitors of IL-1 action - Google Patents

Heterocyclic benzenesulfonylimine derivatives AS inhibitors of IL-1 action

Info

Publication number
ZA949301B
ZA949301B ZA949301A ZA949301A ZA949301B ZA 949301 B ZA949301 B ZA 949301B ZA 949301 A ZA949301 A ZA 949301A ZA 949301 A ZA949301 A ZA 949301A ZA 949301 B ZA949301 B ZA 949301B
Authority
ZA
South Africa
Prior art keywords
inhibitors
pct
action
sec
heterocyclic
Prior art date
Application number
ZA949301A
Other languages
English (en)
Inventor
George Ku
Boyd Lynn Harrison
David Martin Stemerick
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA949301B publication Critical patent/ZA949301B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA949301A 1993-11-29 1994-11-23 Heterocyclic benzenesulfonylimine derivatives AS inhibitors of IL-1 action ZA949301B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15866193A 1993-11-29 1993-11-29

Publications (1)

Publication Number Publication Date
ZA949301B true ZA949301B (en) 1995-08-07

Family

ID=22569128

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA949301A ZA949301B (en) 1993-11-29 1994-11-23 Heterocyclic benzenesulfonylimine derivatives AS inhibitors of IL-1 action

Country Status (20)

Country Link
US (1) US5668143A (de)
EP (1) EP0731792B1 (de)
JP (1) JP3612073B2 (de)
KR (1) KR100351884B1 (de)
CN (1) CN1045596C (de)
AT (1) ATE176225T1 (de)
AU (1) AU682736B2 (de)
CA (1) CA2177146C (de)
DE (1) DE69416324T2 (de)
DK (1) DK0731792T3 (de)
ES (1) ES2129794T3 (de)
FI (1) FI113368B (de)
GR (1) GR3029485T3 (de)
HU (1) HU222819B1 (de)
IL (1) IL111774A (de)
NO (1) NO306158B1 (de)
NZ (1) NZ276570A (de)
TW (1) TW281671B (de)
WO (1) WO1995014670A1 (de)
ZA (1) ZA949301B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044116C (zh) * 1993-11-29 1999-07-14 默里尔药物公司 用作il－1作用抑制剂的苯磺酰亚胺衍生物及其用途
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
AU2002345796A1 (en) * 2001-06-26 2003-03-03 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
KR100687522B1 (ko) * 2005-05-28 2007-02-27 한국화학연구원 2,2-디메틸-3-에스테르-4-알콕시-6-알킬 아미노벤조피란 유도체를 유효성분으로 함유하는 pge2 활성에 관련된 염증질환 치료제
PL2771180T3 (pl) 2011-10-28 2016-12-30 Sposób wytwarzania ultralekkich struktur tekturowych mających znaczną stabilność mechaniczną

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
ATE137225T1 (de) * 1991-02-27 1996-05-15 Merrell Pharma Inc Dihydrochinolin nmda antagonisten
JPH05331169A (ja) * 1992-05-26 1993-12-14 Sumitomo Pharmaceut Co Ltd ベンゾナフチリジン誘導体

Also Published As

Publication number Publication date
CA2177146C (en) 1999-07-06
AU682736B2 (en) 1997-10-16
JPH09506344A (ja) 1997-06-24
CA2177146A1 (en) 1995-06-01
DE69416324D1 (de) 1999-03-11
WO1995014670A1 (en) 1995-06-01
CN1045596C (zh) 1999-10-13
CN1136312A (zh) 1996-11-20
ATE176225T1 (de) 1999-02-15
ES2129794T3 (es) 1999-06-16
EP0731792A1 (de) 1996-09-18
NZ276570A (en) 2001-02-23
FI962236A (fi) 1996-05-28
DE69416324T2 (de) 1999-06-10
US5668143A (en) 1997-09-16
IL111774A (en) 1999-11-30
AU1086895A (en) 1995-06-13
TW281671B (de) 1996-07-21
DK0731792T3 (da) 1999-09-13
NO962156D0 (no) 1996-05-28
KR100351884B1 (ko) 2002-12-31
EP0731792B1 (de) 1999-01-27
FI113368B (fi) 2004-04-15
HU222819B1 (hu) 2003-11-28
HUT76272A (en) 1997-07-28
FI962236A0 (fi) 1996-05-28
JP3612073B2 (ja) 2005-01-19
GR3029485T3 (en) 1999-05-28
NO306158B1 (no) 1999-09-27
HU9601434D0 (en) 1996-07-29
IL111774A0 (en) 1995-01-24
NO962156L (no) 1996-05-28

Similar Documents

Publication Publication Date Title
GR3032506T3 (en) 3-aryl-2-isoxazolines as antiinflammatory agents
EG20693A (en) Isoxazoline compounds as antiinflammatory agents
BR9407239A (pt) Azadioxacicloalquenos substituídos
TW279161B (de)
GR3034005T3 (en) Neuroprotective indolone and related derivatives.
TW281671B (de)
GR3030626T3 (en) 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
HUT75315A (en) N-substituted azabicycloheptane derivatives and use of them, for example, as neuroleptics
FI962301A0 (fi) Substituoidut aminoalkyyliaminopyridiinit